Parameter
| Biomarker | TP53 | Full name | TP53 gene mutation | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Macromolecule | Molecular Weight | / | Core Functional Dimensions | Diagnosis and Prognosis |
| Disease | Pancreatic Neuroendocrine Tumors | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Tissue (IHC, NGS) | ||
| Pathobiological Mechanisms | Tumor suppressor genes, mutations lead to uncontrolled cell cycle checkpoints and enhance invasiveness | ||||
| Clinical Availability Status | Clinical differential core: 90% PanNEC mutation, used to distinguish between PanNET G3 and PanNEC; The prognosis of Pannec with mutation is extremely poor | ||||
| Notes and Dynamics | Combination with RB1 deletion is a molecular feature of PanNEC, which can guide the choice of platinum-based chemotherapy | ||||